Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0009922814566935 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Topiramate treatment of pediatric metabolic dysfunction-associated steatotic liver disease: A descriptive cohort study.
JPEN J Parenter Enteral Nutr
December 2024
Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common disease in children. Lifestyle modification is the primary treatment but difficult to achieve and maintain. Topiramate is a component of an approved weight loss medication (topiramate-phentermine) in children aged 12 years and older but is more commonly used as a single agent, off-label, for pediatric obesity.
View Article and Find Full Text PDFEvaluation of the efficacy and safety of controlled-release phentermine/topiramate in adults with obesity in Korea: A randomized, double-blind, placebo-controlled, phase 4 trial (QUEEN's study).
Diabetes Obes Metab
December 2024
Department of Internal Medicine, Guri Hospital, Hanyang University, College of Medicine, Seoul, Republic of Korea.
Aims: This study evaluated the efficacy and safety of a combination of phentermine and delayed-release topiramate (PHEN/TPM CR) versus placebo as an adjunct to standard lifestyle recommendations in Korean adults.
Materials And Methods: This 56-week, randomized, double-blind, placebo-controlled, phase 4 trial enrolled adults (age 19-70 years) with obesity (BMI ≥ 25 kg/m) at eight sites in South Korea. After a 12-week lifestyle programme, participants were randomly assigned in a 1:1 ratio to receive PHEN/TPM CR or placebo.
Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Dig Dis Sci
November 2024
Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, 300 Cedar St., TAC S241, New Haven, CT, 06519, USA.
Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and resultant steatohepatitis (MASH) have been linked to psychiatric comorbidities. The treatment of MASLD/MASH primarily relies upon weight loss, where achieving a 7% total body weight loss is recommended to improve steatohepatitis. We aimed to determine whether achieving a 7% total body weight loss (TBWL) in MASLD/MASH patients was significantly different in the presence of a mood and/or anxiety disorder in an interdisciplinary clinic that integrates weight management and hepatology care.
View Article and Find Full Text PDFObesity Medications and Their Impact on Cardiovascular Health: A Narrative Review.
Cureus
October 2024
School of Medicine, Louisiana State University (LSU) Health Sciences Center New Orleans, New Orleans, USA.
Obesity is a major global issue linked to cardiovascular diseases (CVDs). While lifestyle changes are the primary treatment, medications are often required for long-term weight management and reducing risk in patients with obesity. The cardiovascular effects of many obesity medications are still being studied.
View Article and Find Full Text PDFEvaluation of Anti-obesity Potential of Leaves.
Arch Razi Inst
April 2024
Department of Biotechnology, KAHER's Dr. Prabhakar Kore Basic Science Research Centre, Belagavi-590010, Karnataka, India.
Obesity has been an important health concern for over a decade, causing serious health issues worldwide. Treatments available for obesity include FDA-approved drugs such as Lorcaserin, Orlistat, Bupropion, combinations of Phentermine and Topiramate, and Sibutramine; however, these have adverse effects on health. To address the said issue, the current study was conducted to evaluate the anti-obesity potential of leaves.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!